BRIDGEWATER, N.J.—Cosette Pharmaceuticals, Inc. (“Cosette”) has obtained the US marketing rights to Betaine Anhydrous for Oral Solution 180gm (“Betaine”) in an agreement with ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) and commenced shipping (NDC #0713-0352-81) to customers this week.
Apurva Saraf, President and CEO of Cosette, stated “This launch is further evidence of Cosette’s ability to partner globally and bring important drugs to the market, and furthers our transformation into a specialty pharmaceutical company. We stay true to our firm belief of Innovating Every Day, to be a trusted partner of choice, and to continue the important work of serving U.S. patients and prescribers.”
Betaine is used by patients with homocystinuria, a rare genetic condition where too much homocysteine builds up in the body. This launch will provide patients with homocystinuria, and the healthcare providers delivering care to those patients, with a safe, efficacious and accessible treatment option.
See the Full Prescribing Information and Instructions for Use for Betaine Anhydrous for Oral Solution, 180 grams. www.dailymed.com
Cystadane® is registered trademark of Recordati Rare Diseases
About Cosette Pharmaceuticals, Inc.:
Cosette Pharmaceuticals, Inc. is a US-based, fully integrated pharmaceutical company with capabilities in product development, manufacturing, and commercial operations. Cosette has a fast-growing portfolio of branded pharmaceuticals consisting of products in the cardiology, women’s health and migraine markets. Cosette has a long history in quality manufacturing of complex dosage forms including topical creams, ointments, oral liquids/solutions and suppositories, which has led to consistent supply to customers and commercialization success. Cosette has corporate and manufacturing facilities in New Jersey and North Carolina, and is supported by more than 350+ dedicated employees across all functional areas. Cosette is backed by Avista Capital Partners, a healthcare focused private equity firm. www.cosettepharma.com